FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma
Season 4, Episode 48, Apr 12, 2021, 08:21 PM
In our exclusive interview, Fowler discussed the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, explained the implications of the regulatory decision on clinical practice, and detailed potential next steps for the PI3Kδ and CK1ε inhibitor.